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Abstract
Visfatin has been proposed as an insulin-mimicking adipocytokine, predominantly secreted from adipose tissue and
correlated with obesity. However, recent studies suggest visfatin may act as a proinflammatory cytokine. Our studies sought
to determine the significance of this adipocytokine and its potential role in the pathogenesis of T2DM. Firstly, we examined
the effects of diabetic status on circulating visfatin levels, and several other adipocytokines, demonstrating that diabetic
status increased visfatin*, TNF-a*** and IL-6*** compared with non-diabetic subjects (*p,0.05, **p,0.01, ***p,0.001,
respectively). We then assessed the effects of an insulin sensitizer, rosiglitazone (RSG), in treatment naı ¨ve T2DM subjects, on
circulating visfatin levels. Our findings showed that visfatin was reduced post-RSG treatment [vs. pre-treatment (*p,0.05)]
accompanied by a reduction in HOMA-IR**, thus implicating a role for insulin in visfatin regulation. Further studies
addressed the intracellular mechanisms by which visfatin may be regulated, and may exert pro-inflammatory effects, in
human abdominal subcutaneous (Abd Sc) adipocytes. Following insulin (Ins) and RSG treatment, our in vitro findings
highlighted that insulin (100 nM), alone, upregulated visfatin protein expression whereas, in combination with RSG (10 nM),
it reduced visfatin*, IKKb** and p-JNK1/2*. Furthermore, inhibition of JNK protein exacted a significant reduction in visfatin
expression (**p,0.01), whilst NF-kB blockade increased visfatin (*p,0.05), thus identifying JNK as the more influential
factor in visfatin regulation. Additional in vitro analysis on adipokines regulating visfatin showed that only Abd Sc
adipocytes treated with recombinant human (rh)IL-6 increased visfatin protein (*p,0.05), whilst rh visfatin treatment, itself,
had no influence on TNF-a, IL-6 or resistin secretion from Sc adipocytes. These data highlight visfatin’s regulation by insulin
and RSG, potentially acting through NF-kB and JNK mechanisms, with only rh IL-6 modestly affecting visfatin regulation.
Taken together, these findings suggest that visfatin may represent a pro-inflammatory cytokine that is influenced by insulin/
insulin sensitivity via the NF-kB and JNK pathways.
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Introduction
Following the recent isolation and characterization of visfatin,
or pre-B-cell colony-enhancing factor (PBEF)/nicotinamide phos-
phoribosyltransferase (Nampt), as a novel adipocytokine, there has
been a rapidly growing interest in this protein, its potential
properties and subsequent role in the development of T2DM and
obesity. Whilst the role of visfatin remains unclear, ablation of the
gene proves fatal in visfatin knockout (KO) mice (2/2), during
early embryogenesis [1]. These findings, in addition to the high
level of evolutionary conservation of the visfatin gene [2], highlight
its fundamental importance and emphasize how visfatin may play
a key functional role in a variety of essential biological processes.
Previous studies have concentrated on the insulin mimetic
properties of visfatin, due to the original work by Fukuhara and
co-workers, with subsequent human studies noting increased
circulating visfatin concentration in states of hyperglycemia and
T2DM, which reduced with insulin treatment [3–6]. In contrast,
several other studies debate the actual insulin-mimetic properties
of visfatin, with such studies identifying a lack of association
between visfatin and insulin resistance in humans [7–11], at either
circulating or mRNA levels.
Following identification of the suggested insulin-mimetic
properties of visfatin, studies have concurrently examined the role
of insulin sensitizers, such as the thiazolidinediones (TZDs), on
visfatin levels, which has resulted in the further generation of
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9conflicting data. As such, treatment of non-diabetic (ND) subjects
with rosiglitazone (RSG) has been shown to increase circulating
visfatin levels [12], whilst, contrastingly, pioglitazone treatment
has led to no apparent change in circulating levels in either T2DM
or ND subjects [13,14]. Assessment of visfatin mRNA levels in
adipose tissue (AT), as a result of RSG treatment in the Otsuka
Long Evans Tokushima Fatty (OLETF) rat (an animal model of
T2DM with obesity), revealed increased mRNA expression levels
in visceral fat depots [15], although decreased visfatin mRNA
expression levels were reported in 3T3-L1 adipocytes [16]. In
pioglitazone treated AT, visfatin mRNA expression in abdominal
subcutaneous (Abd Sc) AT [16] or isolated adipocytes [17]
remained unchanged. Furthermore, studies investigating the
relationship between visfatin expression, adiposity and depot-
specificity in human and rodent AT has also produced conflicting
data [1,7,18–21].
The potential mechanisms involved in visfatin’s activity in AT
has remained largely under-studied beyond its ability to activate
components of the insulin signaling pathway, such as insulin
receptor substrates (IRS)-1/2 [1,22], or PI3-kinase/Akt, by
binding to the insulin receptor at a site distinct to insulin, itself
[1]. Studies have begun to highlight visfatin’s regulation of central
transcription factors, such as nuclear factor (NF)-kB and activator
protein (AP)-1 [23,24]. This has addressed the potential for visfatin
to elicit inflammatory responses [2,24,25], linked with elevated
levels of pro-inflammatory factors, such as TNF-a and IL-6
[10,25,26,27]. However, to date, the findings regarding visfatin’s
inflammatory role in the pathogenesis of T2DM, as well as the
controlling mediators of visfatin regulation, remain unclear.
Therefore, the aims of this study were, firstly, to determine the
systemic levels of visfatin in ND and T2DM subjects, as well as to
establish the influence of RSG on circulating visfatin levels in
newly diagnosed T2DM patients. Secondly, to further clarify
whether an association exists between visfatin expression,
increasing adiposity and depot-specificity in human AT (Abd Sc
vs. Om AT), in addition to several other adipocytokines and
factors implicated in the pathogenesis of the metabolic syndrome.
Lastly, to investigate the potential inflammatory mechanisms via
which visfatin may be regulated within the adipocyte, in addition
to determining if visfatin regulates other pro-inflammatory
adipocytokines, using in vitro analysis.
Materials and Methods
Ethics Statement
All studies were performed with the approval of the South
Birmingham Ethics committee and Coventry and Warwickshire
Ethics committee, with informed written consent obtained from all
subjects prior to enrolment.
Subjects
Fasting serum samples were collected from 34 ND and 30
T2DM subjects [ND BMI: 26.5(mean6SD) 64.4 kg/m
2; Age:
38.9612.4 yrs; T2DM BMI: 37.269.0 kg/m
2;A g e :5 1 . 3 612.6 yrs].
All T2DM patients had at least a 1 yr history of T2DM and remained
on anti-diabetic therapy during sampling. For serum studies,
anthropometric data were collected (Tables 1 & 2). Serum samples
were assessed for glucose, insulin and cytokine levels, as detailed below.
Fasting serum samples were also obtained from a cohort of newly
diagnosed type 2 diabetic patients, who were treated for 10 weeks with
RSG (4 mg twice daily), [BMI: 35.566.0 kg/m
2;A g e :5 5 . 4 611.1 yrs,
n=12]. In addition, matched Abd Sc and Omwhole AT samples were
obtained from a human ND population (n=47, age: 43.868.4 yrs
[mean6SD]; BMI: 29.269.6 kg/m
2) undergoing elective surgery, for
the purpose of matched pair protein analysis. These subjects had no
medical conditions (i.e. hypertension, CVD, thyroid disorders, renal
disorders, diabetes or chronic pain conditions). None of the subjects
were on endocrine therapy (i.e. hormonal replacement therapy (HRT),
tamoxifen, steroids, thyroxine) anti-inflammatory therapy (aspirin,
cyclooxygenase-2 inhibitors), statins, thiazolidinediones (TZDs) or
antihypertensive therapy.
Isolation of Mature Adipocytes
Abd Sc AT was digested in collagenase (2 mg/mL; Worthing-
ton Biochemical, USA) in order to isolate the mature adipocytes,
as previously described [28]. Following isolation, adipocytes were
maintained in phenol red-free DMEM:Ham’s F-12 medium
containing 15 mmol/L glucose, penicillin (100 U/mL) and
streptomycin (100 mg/mL) with the various treatment regimens,
described below.
Treatment of Abd Sc Adipocytes with Visfatin, TNF-a, IL-6,
JNK/NF-kB Inhibitors, Insulin and/or RSG
Mature adipocytes in 1 mL aliquots (containing approximately
500,000 adipocytes) were maintained in 25 cm
2 flasks containing
5 mL phenol red-free DMEM:Ham’s F-12 medium for 48 hours
(hrs), then treated with recombinant human (rh) insulin alone
(100 nM; Sigma UK) with optimal concentrations determined in
previous studies [29–32], or in combination with RSG, (10 nM;
GlaxoSmithKline, UK), rh visfatin alone (1, 100 nM; Phoenix
Pharmaceuticals, USA), or combined with 10 nM RSG, rh TNF-a
(1, 5, 10 ng/mL; Biosource International Inc, Belgium) and rh
IL-6 (1, 5, 10 ng/mL; Sigma-Aldrich, UK) for 48 hrs. For
inhibition studies, adipocytes were incubated for 24 hrs with NF-
kB inhibitor (NF-kB: SN50, 50 mg/mL; Calbiochem, UK) and/or
c-Jun N-terminal Kinase (JNK) inhibitor (SP600125, 10 mM; A.G.
Scientific, Inc., San Diego, CA). For all treatments, untreated
adipocytes maintained in medium for 48 hrs were used as controls,
unless otherwise stated. Viability of adipocytes was assessed using
trypan blue (Sigma) as previously described [28]. Furthermore,
adipocytes remained insulin sensitive, as demonstrated by previous
analysis of multiple adipocytokines, including TNF-a, which
displayed changes in levels with increasing insulin concentration
that otherwise would have remained unchanged within insulin
resistant cells [29–32]. Following incubation (37uC/5%CO2),
adipocytes and their conditioned media were separated by
centrifugation (360 g for 2 minutes). Conditioned media were
removed, aliquoted and stored at 280uC for future use. Adipocyte
protein was extracted using a radio-immunoprecipitation (RIPA)
buffer [29], then stored at 280uC, until required for analysis.
Analysis of Serum Adipokine and Hormone Levels
Serum visfatin levels were assayed using a commercially
available Visfatin C-terminal human EIA Kit (Phoenix Pharma-
ceuticals, Inc. USA; Intra-assay: ,5%; Inter-assay: ,14%). In
addition, serum levels were also assessed to detect levels of TNF-a,
IL-6 (BenderMedSystems, Vienna, Austria), sCD14 (R&D Sys-
tems, Abingdon, UK), leptin, adiponectin and insulin (Linco
Research, St. Charles, MO). Serum levels were analyzed using a
solid phase enzyme-linked immunosorbant assay (TNF-a CV
intra-assay 6?0%, inter-assay 9?3%; IL-6 CV intra-assay 6?2%,
inter-assay 7?0%; sCD14 CV intra-assay 5.4%, inter-assay 6.3%;
Leptin CV intra-assay 2.6%, CV inter-assay 3.863.4%; insulin
CV intra-assay 5?96%, inter-assay 10?360?9%. Fasting glucose
levels were analyzed using a glucose oxidase method (YSL 200
STAT plus). Insulin resistance (HOMA-IR) was derived using a
HOMA equation [33]. Analyses were performed on log
Visfatin in Obesity and Type 2 Diabetes Mellitus
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distributed.
Assessment of Adipocytokine Secretion from Visfatin
Treated Abd Sc Adipocytes
Conditioned media from cultured control (untreated) Abd Sc
adipocytes and visfatin treated adipocytes were assayed using
commercially available human ELISAs for resistin (Phoenix Europe
GmbH, Germany) (Intra-assay CV, ,3%; Inter-assay CV, ,10%;
Minimum Detectable Concentration (sensitivity of assay: 0.016 ng/
mL)), TNF-a (0.1 ng/mL) and IL-6 (16 pg/mL). In addition to this,
conditioned media from cultured control untreated Abd Sc
adipocytes and insulin treated adipocytes, were assayed for IL-6.
Protein Determination & Western Blot Analysis
Protein was extracted from isolated adipocytes using a RIPA
buffer (150 mmol/L NaCl, 1.0% IGEPALH CA-630, 0.5%
sodium deoxycholate, 0.1% SDS, and 50 mmol/L Tris), as
previously documented [29]. Protein concentrations were quan-
tified using the Bio-Rad DC (Detergent Compatible) protein assay
kit [34]. Western blot analysis was performed using a standard
method previously described [32]. In brief, 25–30 mg of protein
was loaded onto a 10% polyacrylamide gel (Geneflow Ltd.,
Fradley, UK), under reducing conditions, then a human visfatin
polyclonal antibody (1:1000; Biogenesis Ltd., Poole, UK), was
utilized. Polyclonal phosphospecific JNK1 and 2 (p-JNK1/2), NF-
kB and IKKb antibodies (1:1750, Biosource International; 1:250
& 1:250, Calbiochem, UK, respectively) were also utilized. Blots
were developed using an anti-rabbit (Visfatin, 1:10,000; p-JNK1/
2, 1:60,000), or anti-mouse (NF-kB, 1:6000; IKKb, 1:10,000)
horseradish-peroxidase secondary antibody (The Binding Site,
UK). Equal protein loading was confirmed using b-actin (Cell
Signaling, UK) expression (Primary antibody, 1:1000; Secondary
antibody, 1:10,000). A chemiluminescent detection system ECL/
ECL
+ (GE Healthcare, Amersham Biosciences, Little Chalfont,
UK) allowed visualization following exposure to X-ray film.
Intensity was then determined using densitometry (GeneTool
software, Syngene, UK).
Immunohistochemical Analysis
Immunohistochemical analysis of normal kidney and AT was
carried out according to previously described methods [28].
Human Abd Sc and Om AT samples were incubated with a
polyclonal antibody to human visfatin (Phoenix pharmaceuticals,
California USA) at a concentration of 1:250. Human kidney tissue
has been previously reported to express visfatin [35,36] and was
therefore utilized as a positive control for visfatin expression. All
tissue slides were developed using a peroxidase substrate kit and
counterstained with Mayer’s hematoxylin.
Extraction of AT RNA and Quantitative Real-Time
Polymerase Chain Reaction
RNA was extracted from whole Abd Sc and Om AT, as well as
differentiated pre-adipocytes, mature isolated Om and Abd Sc
adipocytes (RNeasy Lipid Tissue Mini Kit, Qiagen, UK). RNA
extraction was followed by a DNase digestion step to remove any
contaminating genomic DNA. RNA (200 ng) from each sample,
alongside human macrophage RNA (Yorkshire Biosciences, UK),
was reverse transcribed using a reverse transcriptase (SuperScript
III, Invitrogen, UK) and random hexamers in 20 mL reaction
volumes, according to the manufacturer’s instructions. Messenger
RNA levels were determined using an ABI 7500 real time PCR
Sequence Detection system, as previously outlined [37].
Visfatin gene expression was quantified using a commercially
available TaqMan
TM Gene Expression Assay (Accession number:
NM_005746.2, Applera, Cheshire, UK) and reactions were
carried out in 25 mL volumes on 96 well plates, in a reaction
buffer containing TaqMan Universal PCR Master Mix and 1 mL
cDNA. All reactions were multiplexed with the housekeeping gene
18S, provided as a pre-optimised control probe (Applera,
Cheshire, UK) allowing data to be expressed as delta cycle
threshold (DCt) values (DCt=Ct of 18S gene subtracted from Ct
of gene of interest) in order to correct for differences in the
efficiency of reverse transcription. Measurements were carried out
Table 1. Clinical and Biochemical Characteristics of T2DM
Subjects Compared with Control Subjects.
Control (n=34) T2DM (n=30) P value
Age, yrs 38.9612.4 51.3612.6 0.00021
BMI, kg/m
2 26.564.4 37.269.0 ,0.0001
Sex (M:F) 12:22 24:6 NA
Visfatin, log
ng/mL
11.39
(9.64, 18.97 )
23.01
(11.77, 28.28)
0.008
Insulin, (median
IU/mL (min, max)
11.4
(2.8, 18.1)
11.5
(3.5, 25.7)
N/S
Glucose mmol/L 5.4760.77 8.3662.66 0.0009
HOMA-IR 2.9161.53 4.1661.68 0.043
TNF-a, pg/mL 11.1163.28 16.9616.5 0.00038
IL-6, pg/mL 4.6162.32 7.0362.42 0.00014
sCD14, million IU/mL 1.4560.40 2.861.01 ,0.0001
Leptin, log pg/mL 15.68
(5.89, 33.79)
22.79
(12.18, 45.72)
N/S
Data are presented as mean (6SD), unless otherwise stated. Non-parametric
data have been log transformed in which case they are presented as mean
(interquartile range).
doi:10.1371/journal.pone.0020287.t001
Table 2. Clinical and Biochemical Characteristics of T2DM
Subjects Pre and Post 10 week Rosiglitazone Treatment.
Pre RSG
(n=12)
Post RSG
(n=12)
P
value
Age, yrs 55.4611.1 N/A N/A
BMI, kg/m
2 35.566.0 37.666.7 N/S
Sex (M:F) 1:1 N/A NA
Visfatin, ng/mL 10.2164.23 7.4564.53 0.04
Insulin, IU/mL 15.7967.58 8.3764.02 0.017
Glucose, log
mmol/L
7.97
(7.49, 12.45)
6.58
(5.62, 8.43)
0.018
HOMA-IR 7.8763.96 3.0562.03 0.009
IL-6, log pg/mL 3.43 (2.25, 7.09) 4.10 (2.80, 5.11) N/S
Adiponectin,
log mg/mL
9215.15
(6460.90, 11771.75)
12083.75
(6478.65, 26585.25)
0.04
Leptin, log
pg/mL
23.43
(13.69, 60.70)
26.37
(13.76, 49.81)
N/S
sCD14, log
million IU/mL
2.10
(1.59, 3.21)
2.35
(1.86, 3.15)
N/S
Data are presented as mean (6SD). Non-parametric data have been log
transformed in which case they are presented as mean (interquartile range).
doi:10.1371/journal.pone.0020287.t002
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to exclude potential bias due to averaging of data transformed
through the equation
22DDCt. Statistical analysis was performed
using a paired t-test (SPSS Inc. 15.0, Woking, UK), unless
otherwise stated.
Analysis of Circulating Visfatin Levels
Serum visfatin levels were assayed using a Visfatin C-terminal
human EIA Kit (Phoenix Pharmaceuticals, Inc. USA). Intra-assay:
,5%; Inter-assay: ,14%. TNF-a, IL-6 and insulin levels were
analyzed using a solid phase enzyme-linked immunosorbant assay.
TNF-a CV intra-assay 6?0%, inter-assay 9?3%; IL-6 CV intra-
assay 6?2%, inter-assay 7?0%; insulin CV intra-assay 5?96%, inter-
assay 10?360?9%. Fasting glucose levels were analyzed using a
glucose oxidase method (YSL 200 STAT plus). Insulin resistance
(HOMA-IR) was derived using a HOMA equation [33].
Statistical Analysis
Protein expression data were compared using a student’s t-test,
unless otherwise stated, and are presented as mean relative fold
difference 6 SEM, unless otherwise stated. Data from mRNA
studies underwent analysis, as detailed in the quantitative RT-
PCR section. Correlations were calculated using a Pearsons’
Correlation Coefficient test. The threshold for significance was
p,0.05. All analysis was carried out using the SPSS version 15
(SPSS Inc. Chicago) software package.
Results
Immunohistological Staining of Visfatin in AT
Positive immuno-staining of visfatin (Figure 1) in the cytoplasm
and cell membrane was confirmed in both Om (D) and Abd Sc (E)
AT. Omission of the primary visfatin antibody (C) did not reveal
any positive staining. Human kidney tissue was used as a control,
also undergoing primary antibody omission (A) and positive
immunohistological staining for visfatin (B).
Circulating Visfatin Levels in Non-Diabetic and T2DM
Subjects
Serum visfatin levels were significantly higher in T2DM subjects
in comparison with ND subjects (**p,0.01, Table 1). Pearson
coefficient correlations were carried out to assess the relationship
between circulating visfatin levels and increasing age or BMI, and
a moderate, positive correlation was observed between visfatin and
BMI in ND control subjects (*p,0.05). A positive correlation was
also observed between visfatin and HOMA-IR (*p,0.05). Serum
visfatin levels did not correlate with any other parameters. Serum
analysis revealed a significant elevation in TNF-a (***p,0.001),
IL-6 (***p,0.001), glucose (***p,0.001), HOMA-IR (*p,0.05)
and sCD14 (***p,0.001) levels in T2DM subjects when compared
against ND subjects (Table 1). No significant differences in insulin
concentration were observed between T2DM and ND controls
(Table 1).
Effect of the Insulin Sensitizer, RSG, on Circulating
Visfatin Levels in Newly Diagnosed T2DM Patients
Visfatin levels were measured in newly diagnosed, treatment
naı ¨ve, T2DM patients pre- and post- 10 week treatment with
10 nM RSG. A significant reduction in serum visfatin was
observed in post-RSG treated T2DM subjects when compared
with pre-RSG treatment (*p,0.05, n=12, Table 2). Serum
visfatin concentration did not correlate with any clinical or
biochemical parameters in this cohort (Table 2). Serum analysis
revealed a significant decrease in the circulating levels of insulin
(*p,0.05), glucose (*p,0.05) and HOMA-IR (**p,0.01), follow-
ing RSG treatment, whilst an increase was observed with
adiponectin (*p,0.05). No correlations were observed between
any of the other clinical or biochemical parameters (Table 2).
Visfatin Protein and Gene Expression in Relation to
Adiposity and Depot Specificity
The investigation of visfatin protein expression in relation to
depot specificity in human AT identified that visfatin protein was
significantly higher in Om AT, when compared with paired Abd
Sc AT, independent of BMI (Lean: n=7; Obese: n=6, total:
n=13, ***p,0.001, Figure 2). Furthermore, an association
between increasing adiposity and visfatin expression in human
Abd Sc adipocytes and AT was not observed at either protein or
mRNA level (data not shown). Lastly, differentiated pre-adipocytes
and mature isolated adipocytes (Om and Abd Sc) demonstrated
the presence of visfatin mRNA in isolated adipocytes: differenti-
ated adipocytes DCt=5.761.35(SEM), Om adipocytes DCt=
11.0260.125, Abd Sc adipocytes DCt=11.1660.077. The
mRNA visfatin level in human macrophages was comparable to
that of the mature Om and Abd Sc adipocytes (DCt=
10.9360.074), whilst visfatin expression was significantly lower
in Om and Sc stromal cells, respectively, DCt=12.7560.175, Sc
stromal DCt=16.160.08 (p,0.05).
Effect of Recombinant Human (rh) Insulin on Visfatin
Protein Expression
The influence of increasing rh insulin concentration (Ins 1 nM,
100 nM) on visfatin in isolated human Abd Sc adipocytes was
investigated. From this, it was observed that visfatin protein
expression significantly increased with both concentrations of
insulin, as compared with untreated controls (Control vs. Ins
1 nM, **p,0.01; Control vs. Ins 100 nM, *p,0.05, Figure 3A).
The effect of insulin alone and in combination with RSG on
visfatin in isolated Abd Sc adipocytes was further examined and
determined that RSG 10 nM/Ins 100 nM significantly reduced
visfatin protein expression compared with insulin alone (100 nM)
48 hrs post treatment (*p,0.05, Figure 3B).
Effect of rh Insulin and RSG on JNK1/2 and IKKb Protein
Expression
In mature Abd Sc adipocytes, treatment with Ins 100 nM/RSG
10 nM was shown to significantly reduce IKKband JNK 1/2 protein
expression (*p,0.01 and *p,0.05, respectively) compared with
adipocytes treated with insulin alone (100 nM) (Figures 4A and 4B).
Effect of JNK and NF-kB Inhibition on Visfatin Protein
Expression in Human Isolated Abd Sc Adipocytes
The effects of NF-kB and JNK inhibition on visfatin protein
expression were investigated in mature isolated Abd Sc adipocytes.
These studies identified that visfatin expression was significantly
reduced with JNK inhibition alone (*p,0.05, Figure 5). Similarly,
when NF-kB was inhibited, visfatin expression was markedly
increased in comparison with control (*p,0.05, Figure 5).
Interestingly, when both JNK and NF-kB were inhibited, visfatin
expression was significantly reduced when compared with control
Abd Sc adipocytes (**p,0.01, Figure 5).
Effect of rh TNF-a and IL-6 on Visfatin Protein Expression
in Human Isolated Abd Sc Adipocytes
In human adipocytes, rh IL-6 was observed to significantly
upregulate visfatin protein expression (rh IL-6: Control: 1.060.01
Visfatin in Obesity and Type 2 Diabetes Mellitus
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no significant difference was observed with rh TNF-a treatment
(data not shown).
Effect of rh Visfatin and RSG on NF-kB and pJNK1/2
Protein Expression
In Abd Sc adipocytes treated with rh visfatin (100 nM) alone, or
in combination with RSG (10 nM), no significant effect on protein
expression of either NF-kB or phosphospecific JNK1/2 was
observed (data not shown).
Effect of Visfatin and Insulin on Adipocytokine Secretion
from Mature Isolated Adipocytes into Conditioned Media
Incubation of mature isolated adipocytes with rh visfatin, and
subsequent analysis revealed visfatin to have no influence on
adipocytesecretionof TNF-a, IL-6or resistin.Incubationofmature
isolated adipocytes with rh insulin identified increasing insulin
concentration to upregulate IL-6 secretion (Control: 2.560.3 pg/
mL versus (vs.) Ins 1 nM: 12.061.1 pg/mL, **p,0.01; control vs.
Ins 10 nM: 15.064.2 pg/mL, ***p,0.001; control vs. Ins 100 nM:
3063.6 pg/mL ***p,0.001) (data not shown).
Figure 1. A–E. Photographs of Immunological Staining of Visfatin Protein. This figure shows the immunological staining of visfatin in (A)
human kidney negative (primary antibody omitted); (B) human kidney positive control; (C) human AT PBEF negative (primary antibody omitted); (D)
human Om AT; (E) human Abd Sc AT. Red arrows highlight areas of red staining to show the presence of the visfatin protein.
doi:10.1371/journal.pone.0020287.g001
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This present study contributes to our understanding of the dual
nature of visfatin through insulin and pro-inflammatory mecha-
nisms. Our current in vivo findings identified that T2DM patients
exhibited significantly higher circulating visfatin levels in compar-
ison with ND subjects, in accordance with previous findings [3,4],
but levels decreased upon treatment with RSG. Furthermore, our in
vitro studies demonstrated that insulin upregulated visfatin protein
expression, which was subsequently attenuated by the insulin
sensitizer RSG. The action of insulin on visfatin expression may
occur indirectly, in part, through the up-regulation of IL-6 in Abd
Sc AT as noted by our studies. These studies also established that
visfatin appears to be regulated via both NF-kB and c-Jun Kinase.
Collectively, both the in vivo and in vitro findings suggest a role for
NF-kB and c-Jun Kinase in the stimulation of pro-inflammatory
cytokines including visfatin, IL-6 and TNF-a from human Abd Sc
adipocytes;withIL-6 actingasa partialpositivemediatorforvisfatin
expression. This further implicates human AT as an important site
for the progression of low-grade inflammation in T2DM.
The role of visfatin in relation to increasing adiposity has been
the subject of much debate over recent years [1,7,9,19,38]. Our
present in vivo studies examined this relationship and found a
significant, positive correlation between increasing BMI and
circulating visfatin levels in the ND subjects, albeit a modest
one. This limited effect may have been a result of the narrow
range of BMI within the control cohort. Furthermore, the T2DM
subjects exhibited significantly higher serum levels of visfatin than
their control counterparts. As such, our data suggest that visfatin
levels are influenced by BMI but that in the diabetic state, BMI
ceases to prevail as the major influential factor. Further analysis,
examining visfatin expression from ex vivo human AT, established
Figure 2. Visfatin Protein Expression in Relation to Adiposity
and Depot Specificity. This figure shows the mean relative fold
protein expression of visfatin in omental (Om) versus abdominal (Abd)
adipose tissue depots in matched pairs, from a cohort of lean and obese
subjects, where the Abd Sc depot has been standardized. The
representative Western blots are shown above. Lean samples: n=7 &
Obese samples: n=6; p-values: p,0.001.
doi:10.1371/journal.pone.0020287.g002
Figure 3. A&B. The Effect of Insulin Alone and in Combination with RSG on Visfatin Protein Expression in Isolated Adipocytes. These
figures show the mean relative protein expression (6SEM) of visfatin in isolated human adipocytes treated with insulin (1 nM and 100 nM,
respectively, Figure 3A) and insulin in combination with RSG (Figure 3B), compared with control (untreated adipocytes) as an arbitrary value of 1. The
representative Western blots are shown above (n=4, p-values: p,0.05*, p,0.01**).
doi:10.1371/journal.pone.0020287.g003
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level in Abd Sc and Om tissue - a finding supported by a recent
study carried out in rodents [18]. However, depot specific analysis
of visfatin showed significantly higher protein levels in Om AT
when compared with Abd Sc, confirming the original findings by
Fukuhara et al [7]. Whilst the ex vivo visfatin tissue findings appear
in conflict with the in vivo findings, this may be further complicated
as systemically the production of visfatin may be derived from
other sources, such as the liver, which may affect the specific
influence of AT [39,40]; highlighting the complexity of the
interplay between AT and other tissues, in vivo.
Our findings also showed RSG to down-regulate circulating
visfatin concentrations, paralleled with a significant reduction in
insulin levels, in vivo. This was in contrast to findings with
pioglitazone where visfatin levels remained unaffected. Such a
difference may have occurred due to several factors including the
duration of treatment, the characteristics of the diabetic cohort
and the different properties of the various TZDs [17]. However,
based on our current data, further in vitro analysis evaluated the
influence of insulin and RSG on visfatin in cultured Abd Sc AT.
Our previous in vitro studies on isolated human adipocytes
observed that insulin stimulated the release of various pathogenic
adipocytokines, whilst RSG inhibited their release [29,31,32]. Our
current studies demonstrated that insulin significantly increased
visfatin protein expression, with lower levels producing a greater
response, whilst RSG, in combination with insulin, significantly
lowered visfatin protein expression compared with cells treated
with insulin alone. Therefore, both the in vivo and in vitro data
suggest visfatin is regulated by insulin. The observation that higher
insulin levels lead to lower visfatin expression indicates the
potential for a negative feedback loop. We may, therefore,
speculate that the presence of high insulin levels in the insulin
sensitive cell negates the need for high levels of visfatin and
therefore suppresses its production. In this instance, visfatin may,
potentially, be a marker of insulin resistance, where the cell
perceives lower levels of insulin and greater visfatin production
arises, as a result. Hence RSG may be acting directly on visfatin,
exerting some of its anti-diabetic activities via the reduction of
visfatin levels, in addition to other adipocytokines, or indirectly
due to its insulin sensitizing effects on the cell.
At present, there are limited data regarding visfatin regulation
and the mechanisms through which it may act in human AT.
Previous studies have observed treatment of 3T3-L1 adipocytes
with either rh TNF-a or rh IL-6 to decrease visfatin mRNA
expression levels [26,27]. Therefore, our studies addressed
whether rh TNF-a and/or rh IL-6 could alter visfatin protein
Figure 4. A&B. The Effects of Insulin and RSG on IKKb and JNK1/2 Protein Expression. These figures shows the effect of insulin, alone
(100 nM), and insulin in combination with RSG (Ins 100 nM/RSG 10 nM) on the mean relative fold protein expression (6 SEM) of IKKb (Figure 4A) and
JNK 1/2 (Figure 4B). The representative Western blots are shown above (n=4, p-values: p,0.05*, p,0.001***).
doi:10.1371/journal.pone.0020287.g004
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results of our in vitro experiments suggest a potential mechanism
through which visfatin may be regulated and indicate a possible
cause for elevated visfatin levels in T2DM subjects. The findings
showed that increasing rh IL-6 concentration modestly upregu-
lated visfatin protein expression in Abd Sc adipocytes, comparable
with other studies [8,10,25]. In addition to this, rising insulin
concentrations increased IL-6 secretion using the same in vitro
system. Therefore, taken together, the findings suggest that, in the
diabetic state, high circulating insulin levels may indirectly
contribute to elevated visfatin levels via upregulation of IL-6.
Thus, whilst previous studies have identified that visfatin activates
insulin’s intracellular signalling cascade [1,19], visfatin may be
upregulated in the event of insulin signalling impairment - an
impairment that may result, partly, from the actions of IL-6
altering its functionality, as well as through the effect of
hyperinsulinaemic conditions on the tissue.
In addition to this, our current in vitro studies have identified a
potential pathway through which visfatin may be regulated in the
adipocyte, as noted through the attenuating effects of RSG on p-
JNK 1/2 and NF-kB protein expression. To delineate these,
further studies examined the influence of these intracellular
signalling molecules through the use of JNK and NF-kB inhibitors
in isolated human Abd Sc adipocytes. These in vitro studies
indicated that the use of a JNK inhibitor reduced visfatin protein
expression compared with untreated controls, whilst NF-kB
inhibition led to increased visfatin protein expression. Further-
more, a combination of both inhibitors resulted in the most
significant reduction in visfatin protein expression, compared with
untreated controls, in a similar fashion to the effects noted by JNK
inhibition, alone, suggesting that JNK has an important regulatory
influence on NF-kB in the mediation of visfatin expression. To
date, few studies have investigated the potential relationship
between JNK/NF-kB and visfatin. However, genomic analysis of
the visfatin gene has identified regulatory elements of NF-kB and
AP-1 [41], with another study, in human leukocytes, noting that
visfatin is upregulated by NF-kB p65 binding activity [25].
Furthermore, both NF-kB and AP-1 have been shown to
upregulate visfatin in human amniotic epithelial cells [23]. These
findings, therefore, suggest that JNK and NF-kB pathways are
involved in visfatin regulation in the human adipocyte, with JNK
exerting a more influential role than that of the NF-kB pathway.
These studies also demonstrate that the JNK and NF-kB pathways
are not the sole mechanisms governing visfatin regulation and, as
with many other adipocytokines, a delicate interplay exists
between various intracellular signalling mechanisms. Hence,
further studies are required to delineate, in full, the intracellular
pathways that govern visfatin.
Although visfatin is presently the focus of intense study, to
date, many of the current findings show inconsistencies with
regard to visfatins role in the pathogenesis of obesity-mediated
T2DM and the metabolic syndrome. However, it is evident
that significant associations between visfatin and inflammatory
disease states do exist [42–44]. This, perhaps, is not surprising
considering AT is comprised of a variety of cells other than
adipocytes, including macrophages and stromal cells, which are
also known to express visfatin. However, this study has
highlighted the role of the adipocyte within AT in relation to
visfatin, whilst other studies have focused on macrophage
function in this capacity [45,46]. The dichotomous nature of
the adipocyte, regarding metabolism and immunity, combined
with it being the major constituent of AT, makes determining
the significance of visfatin in adipocyte biology of fundamental
importance in elucidating its function.
Our present findings demonstrate that rh visfatin does not
influence inflammatory adipocytokines, such as IL-6, TNF-a and
resistin, implicating other factors in visfatin mediated activity.
Our studies do appear to cast light on the mechanisms governing
visfatin’s expression in human adipocytes, with these findings
suggesting visfatin regulation by Ins/RSG and IL-6 is mediated,
in part, through JNK and NF-kB activation. This interaction
represents a significant insight into visfatin’s metabolic regulation
in human AT and further reflects how visfatin represents a
relevant adipocytokine in metabolic disease. Furthermore, our
findings highlight the reduction of visfatin, in combination with
several other cytokines, during RSG treatment of T2DM
patients. This, in conjunction with our previous data, also
showing RSG to lower other pathogenic factors [29,31,32],
represents a novel finding that may underlie the clinical,
metabolic and vascular effects of RSG. Finally, although visfatin’s
role in the pathogenesis of obesity and T2DM, as yet, remains
somewhat controversial, it seems that visfatin does not appear to
be a mere bystander and its pathological, biological and
functional state and influence, may depend on the metabolic
state in which it is found.
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Figure 5. The Effects of JNK and NF-kB Inhibition on Visfatin
Protein Expression in Human Adipocytes. This figure shows the
effect of JNK and NF-ZB blockade, alone and in combination, on the
mean relative fold protein expression (6SEM) of visfatin in isolated Abd
Sc adipocytes compared with control (untreated adipocytes), given an
arbitrary value of one. The representative Western blots are shown
above (n=4, p-values: p,0.05*, p,0.01**).
doi:10.1371/journal.pone.0020287.g005
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